A Randomized, Open-label, Single Dose, 3-Period, 6-Sequence Cross-Over Trial to Investigate the Relative Bioavailability of Apraglutide Versus the Reference Formulation Following Subcutaneous Administrations.

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504430-22-00

Acronym

TA799-018

Enrollment

Registered

2023-05-16

Start date

2023-05-23

Completion date

2023-09-22

Last updated

2023-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

None listed

Sex/Gender

All

Age

18 Years to No maximum

Netherlands

None listed

Source: EU CTIS · Data processed: Feb 4, 2026